Renaissance Technologies (RenTech)'s HRTX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.72 M shares of Heron Therapeutics, Inc. (HRTX) worth $1.37 M, representing 0.00% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in HRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 1.59 M shares. Largest reduction occurred in Q4 2025, reducing 939,099 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Heron Therapeutics (HRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Heron Therapeutics (HRTX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -197,600 | Reduce 10.31% | 1.72 M | $0.80 |
| Q4 2025 | -939,099 | Reduce 32.89% | 1.92 M | $1.30 |
| Q3 2025 | +165,660 | Add 6.16% | 2.85 M | $1.26 |
| Q2 2025 | +414,839 | Add 18.24% | 2.69 M | $2.07 |
| Q1 2025 | +1.09 M | Add 91.33% | 2.27 M | $2.20 |
| Q4 2024 | -819,398 | Reduce 40.80% | 1.19 M | $1.53 |
| Q3 2024 | +14,398 | Add 0.72% | 2.01 M | $1.99 |
| Q2 2024 | -412,686 | Reduce 17.15% | 1.99 M | $3.50 |
| Q1 2024 | +523,186 | Add 27.78% | 2.41 M | $2.77 |
| Q4 2023 | +1.59 M | Add 546.52% | 1.88 M | $1.70 |
| Q3 2023 | -767,800 | Reduce 72.50% | 291,300 | $1.03 |
| Q2 2023 | -81,736 | Reduce 7.16% | 1.06 M | $0.00 |
| Q1 2023 | +814,336 | Add 249.41% | 1.14 M | $0.00 |
| Q4 2022 | +326,500 | New Buy | 326,500 | $0.00 |
| Q2 2021 | -162,600 | Sold Out | 0 | $0.00 |
| Q1 2021 | +162,600 | New Buy | 162,600 | $16.21 |
| Q4 2020 | -134,800 | Sold Out | 0 | $0.00 |
| Q3 2020 | -105,000 | Reduce 43.79% | 134,800 | $14.82 |
| Q2 2020 | -812,092 | Reduce 77.20% | 239,800 | $14.71 |
| Q1 2020 | +870,892 | Add 481.16% | 1.05 M | $11.74 |
| Q4 2019 | +181,000 | New Buy | 181,000 | $23.50 |
| Q3 2019 | -97,400 | Sold Out | 0 | $0.00 |
| Q2 2019 | +97,400 | New Buy | 97,400 | $18.59 |
| Q4 2018 | -134,100 | Sold Out | 0 | $0.00 |
| Q3 2018 | -258,400 | Reduce 65.83% | 134,100 | $31.65 |
| Q2 2018 | +392,500 | New Buy | 392,500 | $38.85 |
| Q1 2018 | -79,800 | Sold Out | 0 | $0.00 |
| Q4 2017 | +79,800 | New Buy | 79,800 | $18.10 |
| Q3 2015 | -48,100 | Sold Out | 0 | $0.00 |
| Q2 2015 | +48,100 | New Buy | 48,100 | $31.16 |
Renaissance Technologies (RenTech)'s Heron Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Heron Therapeutics, Inc. (HRTX) in Q2 2015, acquiring 48,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Heron Therapeutics, Inc. (HRTX) for 30 quarters since Q2 2015.
Renaissance Technologies (RenTech)'s largest addition to Heron Therapeutics, Inc. (HRTX) was in Q4 2023, adding 1,883,300 shares worth $3.2 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,718,300 shares of Heron Therapeutics, Inc. (HRTX), valued at approximately $1.37 M.
As of the Q1 2026 filing, Heron Therapeutics, Inc. (HRTX) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Heron Therapeutics, Inc. (HRTX) was 2,854,999 shares, as reported at the end of Q3 2025.